← Back to headlines
BioXcel Therapeutics Files for Bankruptcy and Finalizes Asset Sale to Teva Pharmaceuticals
Struggling biotechnology company BioXcel Therapeutics has filed for Chapter 11 bankruptcy protection and formally entered into an asset sale agreement to transfer its remaining intellectual property and product portfolio to Israeli drugmaker Teva Pharmaceuticals.
28 Aug, 10:00 — 28 Aug, 10:25
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
taiwan-news
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 2 regions9/34
US1Taiwan1
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
seeking-alphaMixed18h ago
BioXcel files for Chapter 11, will sell assets to Teva
Read full article →taiwan-newsMostly Factual19h ago
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals - Taiwan News
BioXcel Therapeutics Enters Into Asset Sale Agreement with Teva Pharmaceuticals Taiwan News
Read full article →Coverage Timeline
First report: taiwan-news · 28 Aug, 10:00|Full coverage: 2 · 25m|Window: 25m
Left-leaningCenterRight-leaning
